- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.08. | P3 Health Partners passt Darlehensvertrag an: Laufzeit verlängert und Zinskonditionen neu geregelt | 3 | Investing.com Deutsch | ||
| 29.08. | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.08. | P3 Health Partners: EPS verfehlt Schätzungen um 6,12 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 15.08. | P3 Health Partners outlines $120M-$170M EBITDA improvement opportunity for 2026 while strengthening payer contracts | 1 | Seeking Alpha | ||
| 14.08. | P3 Health Partners Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| P3 HEALTH PARTNERS Aktie jetzt für 0€ handeln | |||||
| 14.08. | P3 Health Partners GAAP EPS of -$6.23 misses by $1.93, revenue of $355.7M misses by $3.73M | 2 | Seeking Alpha | ||
| 09.07. | P3 Health Partners beruft CEO Aric Coffman nach Rücktritt in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 09.07. | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | P3 Health shares dip as TD Cowen cuts price target to $8 | 1 | Investing.com | ||
| 28.05. | P3 Health-Aktien fallen - TD Cowen Kursziel auf 8 US-Dollar senkt | 2 | Investing.com Deutsch | ||
| 16.05. | P3 Health Partners reaffirms $130M EBITDA improvement plan as operational initiatives accelerate in 2025 | 1 | Seeking Alpha | ||
| 15.05. | P3 Health Partners GAAP EPS of -$6.28 beats by $1.64, revenue of $373.2M beats by $11.13M | 1 | Seeking Alpha | ||
| 14.05. | What to Expect from P3 Health Partners' Earnings | 1 | Benzinga.com | ||
| 04.04. | P3 Health Partners Announces 1-for-50 Reverse Stock Split | - | Investing.com | ||
| 04.04. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | P3 Health Partners Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 28.03. | P3 Health stock neutral rating reiterated after earnings miss | 2 | Investing.com | ||
| 28.03. | P3 Health Partners targets profitability in 2025 with adjusted EBITDA guidance of up to $5M | 1 | Seeking Alpha | ||
| 12.11.24 | P3 Health Partners Announces Third Quarter 2024 Results | 224 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,112 | -0,88 % | Sernova Corp.: Sernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference | ||
| ATOSSA THERAPEUTICS | 0,680 | -0,44 % | Atossa Genetics stock rating reiterated by H.C. Wainwright on FDA meeting plans | ||
| PING AN HEALTHCARE | 2,516 | +1,49 % | Ping An Healthcare and Technology Company Limited: Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth | HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,015 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| CO-DIAGNOSTICS | 0,260 | -0,76 % | Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results | SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development... ► Artikel lesen | |
| VERU | 3,820 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
| CYTOSORBENTS | 0,853 | +5,96 % | CytoSorbents bei H.C. Wainwright: Strategisches Wachstum und regulatorische Herausforderungen | ||
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
| VOLITIONRX | 0,631 | 0,00 % | H.C. Wainwright bestätigt Kaufempfehlung für VolitionRX nach Partnerschaft mit Werfen | ||
| EKSO BIONICS | 4,070 | 0,00 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| IMUNON | 4,900 | +2,51 % | Imunon, Inc.: IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement | LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company... ► Artikel lesen | |
| BEYOND AIR | 2,260 | 0,00 % | Beyond Air, Inc. - 8-K, Current Report | ||
| AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| NOVACYT | 0,449 | -5,87 % | Novacyt S.A. - Liquidity Agreement Monthly Update and TVR | ||
| AROVELLA THERAPEUTICS | 0,041 | 0,00 % | AROVELLA THERAPEUTICS LIMITED: 2025 ESG Report |
P3 HEALTH PARTNERS INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,200 (-2,25 %) liegt der Kurs bei 8,680 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu P3 HEALTH PARTNERS INC finden Sie auf Wallstreet Online.